Conor expands COSTAR II
This article was originally published in The Gray Sheet
Executive Summary
FDA approves Conor Medsystem's plan to expand enrollment of the COSTAR II U.S. pivotal trial of the CoStar cobalt chromium paclitaxel-eluting stent to 85 sites and 1,700 patients. An initial IDE for the trial was approved by FDA in March. The trial randomizes patients with single or multi-vessel de novo coronary lesions to receive either CoStar or Boston Scientific's Taxus paclitaxel-eluting stent. CoStar is available in Europe and India...
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.